aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2023-19-4-444-456ateroskleroz-1015Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSАссоциации адипокинов с ишемической болезнью сердца у людей молодого и среднего возрастаAssociations of adipokines with coronary heart disease in young and middle-aged peoplehttps://orcid.org/0000-0001-5316-4664ГарбузоваЕ. В.GarbuzovaE. V.

Евгения Витальевна Гарбузова - кандидат медицинских наук, научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека.

630089, Новосибирск, ул. Бориса Богаткова, 175/1

Evgeniia V. Garbuzova - candidate of medical sciences, researcher, laboratory of genetic and environmental determinants of the human life cycle.

175/1, Boris Bogatkov str., Novosibirsk, 630089

stryukova.j@mail.ruhttps://orcid.org/0000-0001-7875-1566ХудяковаА. Д.KhudiakovaA. D.

Алёна Дмитриевна Худякова - кандидат медицинских наук, зав. лабораторией генетических и средовых детерминант жизненного цикла человека.

630089, Новосибирск, ул. Бориса Богаткова, 175/1

Alena D. Khudiakova - candidate of medical sciences, head of the laboratory of genetic and environmental determinants of the human life cycle.

175/1, Boris Bogatkov str., Novosibirsk, 630089

alene.elene@gmail.comАлексеевС. Е.AlekseevS. E.

Станислав Евгеньевич Алексеев - ординатор по специальности терапия.

630089, Новосибирск, ул. Бориса Богаткова, 175/1

Stanislav е. Alekseev - resident in the specialty therapy.

175/1, Boris Bogatkov str., Novosibirsk, 630089

stanislavalexeev1996@gmail.comНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»РоссияResearch Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of SciencesRussian Federation202315122023194444456Copyright © Гарбузова Е.В., Худякова А.Д., Алексеев С.Е., 20232023Гарбузова Е.В., Худякова А.Д., Алексеев С.Е.Garbuzova E.V., Khudiakova A.D., Alekseev S.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/1015

Целью данного обзора являлось найти ответ на вопрос: «Существует ли ассоциация адипокинов (адипонектин, адипсин, интерлейкин-6, липокалин-2, PAI-1, резистин, MCP-1, лептин, TNF-α, висфатин, оментин-1) с ишемической болезнью сердца (ИБС) и абдоминальным ожирением у лиц до 65 лет?». В анализ включались публикации последних 10 лет (2013–2023 гг.), в которых исследовались больные ИБС в возрасте от 18 до 65 лет. Обнаружено, что крупные исследования и метаанализы указывают на большой вклад адипоцитокинов в развитие и течение ИБС. Исходя из этого, весьма актуальным представляется изучение адипоцитокинового профиля у людей молодого и среднего возраста с ИБС, особенно на фоне абдоминального ожирения.

The purpose of this review was to find an answer to the question: “Is there an association of adipokines (adiponectin, adipsin, interleukin-6, lipocalin-2, PAI-1, resistin, MCP-1, leptin, TNF-α, visfatin, omentin-1) with coronary artery disease and abdominal obesity in people under 65 years of age?”. Articles investigating patients aged 18 to 65 years with coronary heart disease were included. The analysis included only publications of the last 10 years (2013–2023). As a result of the analyzed literature, most of the publications of the last 10 years are devoted to studies conducted on persons over 65 years of age. At the same time, the available large studies and meta-analyses indicate a large contribution of adipocytokines to the development and course of coronary heart disease. Based on this, it is very relevant to study the adipocytokine profile in young and middle-aged people with coronary heart disease, especially against the background of AO.

адипоцитокиныИБСадипонектинадипсининтерлейкин-6липокалин-2PAI-1резистинMCP-1лептинTNF-αвисфатиноментин-1молодой и средний возрастadipocytokinesCHDadiponectinadipsininterleukin-6lipocalin-2PAI-1resistinMCP-1leptinTNF-αvisfatinomentin-1young and middle ageИсследование выполнено в рамках Бюджетной темы № 122031700115-7, при поддержке гранта Президента РФ № МК-1641.2022.3This research was funded by (1) budget theme on State Assignment No. 122031700115-7; (2) grant of the President of the Russian Federation No. MK-1641.2022.3ReferencesШальнова С.А., Конради А.О., Карпов Ю.А., Концевая А.В., Деев А.Д., Капустина А.В., Худяков М.Б., Шляхто Е.В., Бойцов С.А. Анализ смертности от сердечно-сосудистых заболеваний в 12 регионах Российской Федерации, участвующих в исследовании «Эпидемиология сердечнососудистых заболеваний в различных регионах России». Рос. кардиол. журн., 2012; 5: 6–11.Shalnova S.A., Konradi A.O., Karpov Yu.A., Kontsevaya A.V., Deev A.D., Kapustina A.V., Khudyakov M.B., Shlyakhto E.V., Boytsov S.A. Cardiovascular mortality in 12 Russian Federation regions – participants of the “Cardiovascular disease epidemiology in Russian regions” study. Russian Journal of Cardiology, 2012; 5: 6–11. (In Russ.).Научно-организационный комитет проекта ЭССЕРФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследования. Профилакт. медицина, 2013; 16 (6): 25–34.Nauchnoorganizatsionnyĭ komitet proekta ÉSSE-RF. Epidemiology of cardiovascular diseases in different regions of Russia (esse-rf). The rationale for and design of the study. Profilakticheskaya Meditsina, 2013; 16 (6): 25–34. (In Russ.).Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Рос. кардиол. журн., 2018; 6: 7–122. doi: 10.15829/1560-4071-20186-7-122Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology, 2018; 6: 7–122. (In Russ.). doi: 10.15829/1560-4071-2018-67-122Ural D., Kiliçkap M., Göksülük H., Karaaslan D., Kayikçioǧlu M., Özer N., Barçin C., Yilmaz M.B., Abaci A., Şengül Ş., Arinsoy T., Erdem Y., Sanisoǧlu Y., Şahin M., Tokgözoǧlu L. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars., 2018; 46: 577–590. doi: 10.5543/tkda.2018.62200Ural D., Kiliçkap M., Göksülük H., Karaaslan D., Kayikçioǧlu M., Özer N., Barçin C., Yilmaz M.B., Abaci A., Şengül Ş., Arinsoy T., Erdem Y., Sanisoǧlu Y., Şahin M., Tokgözoǧlu L. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars., 2018; 46: 577–590. doi: 10.5543/tkda.2018.62200Побожева И.А., Разгильдина Н.Д., Полякова Е.А., Пантелеева А.А., Беляева О.Д., Нифонтов С.Е., Галкина О.В., Колодина Д.А., Беркович О.А., Баранова Е.И., Пчелина С.Н., Мирошникова В.В. Экспрессия гена адипонектина в эпикардиальной и подкожной жировой ткани при ишемической болезни сердца. Кардиология, 2020; 60 (4): 62–69. doi: 10.18087/cardio.2020.4.n517Pobozheva I.A., Razgildina N.D., Polyakova E.A., Panteleeva A.A., Belyaeva O.D., Nifontov S.E., Galkina O.V., Kolodina D.A., Berkovich O.A., Baranova E.I., Pchelina S.N., Miroshnikova V.V. Epicardial and subcutenious adipose tissue adiponectin gene expression in coronary artery disease patients. Kardiologiia, 2020; 60 (4): 62–69. doi: 10.18087/cardio.2020.4.n517 (In Russ.).Picard F.A., Gueret P., Laissy J.P., Champagne S., Leclercq F., Carrié D., Juliard J.M., Henry P., Niarra R., Chatellier G., Steg P.G. Epicardial Adipose Tissue Thickness Correlates with the Presence and Severity of Angiographic Coronary Artery Disease in Stable Patients with Chest Pain. PLoS ONE, 2014; 9 (10): e110005. doi: 10.1371/journal.pone.0110005Picard F.A., Gueret P., Laissy J.P., Champagne S., Leclercq F., Carrié D., Juliard J.M., Henry P., Niarra R., Chatellier G., Steg P.G. Epicardial Adipose Tissue Thickness Correlates with the Presence and Severity of Angiographic Coronary Artery Disease in Stable Patients with Chest Pain. PLoS ONE, 2014; 9 (10): e110005. doi: 10.1371/journal.pone.0110005Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Рос. кардиол. журн., 2020; 25 (11): 4076. doi: 10.15829/1560-4071-202040762020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology, 2020; 25 (11): 4076. (In Russ.). doi: 10.15829/15604071-2020-4076Петренко Ю.В., Герасимова К.С., Новикова В.П. Биологическая и патофизиологическая значимость адипонектина. Педиатр, 2019; 10 (2): 83–87. doi: 10.17816/PED10283-87Petrenko Yu.V., Gerasimova K.S., Novikova V.P. Biological and pathophysiological role of adiponectin. Pediatrician (St. Petersburg), 2019; 10 (2): 83–87. doi: 10.17816/PED10283-87 (In Russ.).Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., Yeh J., Best L.G. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 2005; 25 (3): e15– e16. doi: 10.1161/01.ATV.0000153090.21990.8cLindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., Yeh J., Best L.G. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol., 2005; 25 (3): e15– e16. doi: 10.1161/01.ATV.0000153090.21990.8cSattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., Danesh J., Whincup P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006; 114 (7): 623–629. doi: 10.1161/CIRCULATIONAHA.106.618918Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., Danesh J., Whincup P.H. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation, 2006; 114 (7): 623–629. doi: 10.1161/CIRCULATIONAHA.106.618918Diah M., Lelo A., Lindarto D., Mukhtar Z. Plasma Concentrations of Adiponectin in Patients with Coronary Artery Disease and Coronary Slow Flow. Acta Med. Indones, 2019; 51 (4): 290–295.Diah M., Lelo A., Lindarto D., Mukhtar Z. Plasma Concentrations of Adiponectin in Patients with Coronary Artery Disease and Coronary Slow Flow. Acta Med. Indones, 2019; 51 (4): 290–295.Полякова Е.А. Низкий уровень адипонектина в крови как фактор риска тяжелого течения ишемической болезни сердца. Атеросклероз и дислипидемии, 2022; 1 (46): 47–56. doi: 10.34687/22198202.JAD.2022.01.0005Polyakova E.A. Low level of adiponectin in the blood as a risk factor for severe coronary heart disease. Atherosclerosis and Dyslipidemia, 2022; 1 (46): 47–56. doi: 10.34687/2219-8202.JAD.2022.01.0005 (In Russ.).Hao G., Li W., Guo R., Yang J.G., Wang Y., Tian Y., Liu M.Y., Peng Y.G., Wang Z.W. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis, 2013; 228 (1): 29–35. doi: 10.1016/j.atherosclerosis.2013.02.018Hao G., Li W., Guo R., Yang J.G., Wang Y., Tian Y., Liu M.Y., Peng Y.G., Wang Z.W. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of prospective studies. Atherosclerosis, 2013; 228 (1): 29–35. doi: 10.1016/j.atherosclerosis.2013.02.018Sook Lee E., Park S.S., Kim E., Sook Yoon Y., Ahn H.Y., Park C.Y., Ho Yun Y., Woo Oh.S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and metaanalysis. Int. J. Epidemiol., 2013; 42 (4): 1029–1039. doi: 10.1093/ije/dyt087Sook Lee E., Park S.S., Kim E., Sook Yoon Y., Ahn H.Y., Park C.Y., Ho Yun Y., Woo Oh.S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and metaanalysis. Int. J. Epidemiol., 2013; 42 (4): 1029–1039. doi: 10.1093/ije/dyt087Wannamethee S.G., Welsh P., Whincup P.H., Sawar N., Thomas M.C., Gudnarsson V., Sattar N. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur. J. Cardiovasc. Prev. Rehabil., 2011; 18 (1): 65–71. doi: 10.1097/HJR.0b013e32833b09d9Wannamethee S.G., Welsh P., Whincup P.H., Sawar N., Thomas M.C., Gudnarsson V., Sattar N. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association? Eur. J. Cardiovasc. Prev. Rehabil., 2011; 18 (1): 65–71. doi: 10.1097/HJR.0b013e32833b09d9Yang L., Li B., Zhao Y., Zhang Z. Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis. Lipids Health Dis., 2019; 18 (1): 227. doi: 10.1186/s12944019-1168-3Yang L., Li B., Zhao Y., Zhang Z. Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis. Lipids Health Dis., 2019; 18 (1): 227. doi: 10.1186/s12944019-1168-3Lo J.C., Ljubicic S., Leibiger B., Kern M., Leibiger I.B., Moede T., Kelly M.E., Chatterjee Bhowmick D., Murano I., Cohen P., Banks A.S., Khandekar M.J., Dietrich A., Flier J.S., Cinti S., Blüher M., Danial N.N., Berggren P.O., Spiegelman B.M. Adipsin is an adipokine that improves β cell function in diabetes. Cell, 2014; 158 (1): 41–53. doi: 10.1016/j.cell.2014.06.005Lo J.C., Ljubicic S., Leibiger B., Kern M., Leibiger I.B., Moede T., Kelly M.E., Chatterjee Bhowmick D., Murano I., Cohen P., Banks A.S., Khandekar M.J., Dietrich A., Flier J.S., Cinti S., Blüher M., Danial N.N., Berggren P.O., Spiegelman B.M. Adipsin is an adipokine that improves β cell function in diabetes. Cell, 2014; 158 (1): 41–53. doi: 10.1016/j.cell.2014.06.005Василенко М.А., Кириенкова Е.В., Скуратовская Д.А. Затолокин П.А, Миронюк Н.И., Литвинова Л.С. Роль продукции адипсина и лептина в формировании инсулинорезистентности у больных абдоминальным ожирением. Докл. АН, 2017; 475 (3): 336–341. doi: 10.7868/S0869565217210228Vasilenko M.A., Kirienkova E.V., Skuratovskaia D.A., Zatolokin P.A., Mironyuk N.I., Litvinova L.S. The role of adipsin and leptin production in the formation of insulin resistance in abdominal obesity patients. Acad. Sci. Rep., 2017; 475 (3): 336–341. doi: 10.7868/s0869565217210228 (In Russ.).Ohtsuki T., Satoh K., Shimizu T., Ikeda S., Kikuchi N., Satoh T., Kurosawa R., Nogi M., Sunamura S., Yaoita N., Omura J., Aoki T., Tatebe S., Sugimura K., Takahashi J., Miyata S., Shimokawa H. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. J. Am. Heart Assoc., 2019; 8 (23): e013716. doi: 10.1161/jAHA.119.013716Ohtsuki T., Satoh K., Shimizu T., Ikeda S., Kikuchi N., Satoh T., Kurosawa R., Nogi M., Sunamura S., Yaoita N., Omura J., Aoki T., Tatebe S., Sugimura K., Takahashi J., Miyata S., Shimokawa H. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. J. Am. Heart Assoc., 2019; 8 (23): e013716. doi: 10.1161/jAHA.119.013716Sun R., Qiao Y., Yan G., Wang D., Zuo W., Ji Z., Zhang X., Yao Y., Ma G., Tang C. Association between serum adipsin and plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease. J. Thorac. Dis., 2021; 13 (4): 2414–2425. doi: 10.21037/jtd-21-259Sun R., Qiao Y., Yan G., Wang D., Zuo W., Ji Z., Zhang X., Yao Y., Ma G., Tang C. Association between serum adipsin and plaque vulnerability determined by optical coherence tomography in patients with coronary artery disease. J. Thorac. Dis., 2021; 13 (4): 2414–2425. doi: 10.21037/jtd-21-259Рагино Ю.И., Щербакова Л.В., Облаухова В.И., Полонская Я.В., Стахнева Е.М., Кузьминых Н.А., Каштанова Е.В. Адипокины крови у молодых людей с ранней ишемической болезнью сердца на фоне абдоминального ожирения. Кардиология, 2021; 61 (4): 32–38. doi: 10.18087/cardio.2021.4.n1369Ragino Yu.I., Shcherbakova L.V., Oblaukhova V.I., Polonskaya Ya.V., Stakhneva E.M., Kuzminykh N.A., Kashtanova E.V. Blood Adipokins in Young People with Early Ischemic Heart Disease on the Background of Abdominal Obesity. Kardiologiia, 2021; 61 (4): 32– 38. doi: 10.18087/cardio.2021.4.n1369 (In Russ.).de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried S.K., Gong D.W., Shuldiner A.R., Pollin T.I., McLenithan J.C. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56 (6): 1655–1661. doi: 10.2337/db06-1506de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., Ndubuizu K., Patil S., Schwartz A., Kligman M., Fried S.K., Gong D.W., Shuldiner A.R., Pollin T.I., McLenithan J.C. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 2007; 56 (6): 1655–1661. doi: 10.2337/db06-1506Bai P., Abdullah F., Lodi M., Sarhadi M., Dilip A., Shahab S., Yasir F., Jahangir M. Association Between Coronary Artery Disease and Plasma Omentin-1 Levels. Cureus, 2021; 13 (8): e17347. doi: 10.7759/cureus.17347Bai P., Abdullah F., Lodi M., Sarhadi M., Dilip A., Shahab S., Yasir F., Jahangir M. Association Between Coronary Artery Disease and Plasma Omentin-1 Levels. Cureus, 2021; 13 (8): e17347. doi: 10.7759/cureus.17347Onur I., Oz F., Yildiz S., Oflaz H., Sigirci S., Elitok A., Pilten S., Karaayvaz E.B., Cizgici A.Y., Kaya M.G., Onur S.T., Sahin I., Dinckal H.M. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology, 2014; 65 (10): 896–900. doi: 10.1177/0003319713511322Onur I., Oz F., Yildiz S., Oflaz H., Sigirci S., Elitok A., Pilten S., Karaayvaz E.B., Cizgici A.Y., Kaya M.G., Onur S.T., Sahin I., Dinckal H.M. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology, 2014; 65 (10): 896–900. doi: 10.1177/0003319713511322Matloch Z., Kratochvílová H., Cinkajzlová A., Kopecký P., Pořízka M., Haluzíková D., Lindner J., Mráz M., Kloučková J., Lacinová Z., Haluzík M. Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease. Physiol. Res., 2018; 67 (6): 881–890. doi: 10.33549/physiolres.933909Matloch Z., Kratochvílová H., Cinkajzlová A., Kopecký P., Pořízka M., Haluzíková D., Lindner J., Mráz M., Kloučková J., Lacinová Z., Haluzík M. Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease. Physiol. Res., 2018; 67 (6): 881–890. doi: 10.33549/physiolres.933909Baig M., Alghalayini K.W., Gazzaz Z.J., Atta H. Association of Serum Omentin-1, Chemerin, and Leptin with Acute Myocardial Infarction and its Risk Factors. Pak. J. Med. Sci., 2020; 36 (6): 1183–1188. doi: 10.12669/pjms.36.6.2372Baig M., Alghalayini K.W., Gazzaz Z.J., Atta H. Association of Serum Omentin-1, Chemerin, and Leptin with Acute Myocardial Infarction and its Risk Factors. Pak. J. Med. Sci., 2020; 36 (6): 1183–1188. doi: 10.12669/pjms.36.6.2372Zhou J.P., Tong X.Y., Zhu L.P., Luo J.M., Luo Y., Bai Y.P., Li C.C., Zhang G.G. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J. Atheroscler. Thromb., 2017; 24 (9): 940–948. doi: 10.5551/jat.37440Zhou J.P., Tong X.Y., Zhu L.P., Luo J.M., Luo Y., Bai Y.P., Li C.C., Zhang G.G. Plasma Omentin-1 Level as a Predictor of Good Coronary Collateral Circulation. J. Atheroscler. Thromb., 2017; 24 (9): 940–948. doi: 10.5551/jat.37440Saely C.H., Leiherer A., Muendlein A., Vonbank A., Rein P., Geiger K., Malin C., Drexel H. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief., 2015; 6: 158–161. doi: 10.1016/j.dib.2015.11.065Saely C.H., Leiherer A., Muendlein A., Vonbank A., Rein P., Geiger K., Malin C., Drexel H. Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief., 2015; 6: 158–161. doi: 10.1016/j.dib.2015.11.065Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J. Am. Coll. Cardiol., 2018; 71 (20): 2360–2372. doi: 10.1016/j.jacc.2018.03.509Packer M. Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. J. Am. Coll. Cardiol., 2018; 71 (20): 2360–2372. doi: 10.1016/j.jacc.2018.03.509Dahl T.B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., Damås J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S.S., Krohg-Sørensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 2007; 115 (8): 972–80. doi: 10.1161/CIRCULATIONAHA.106.665893Dahl T.B., Yndestad A., Skjelland M., Øie E., Dahl A., Michelsen A., Damås J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Frøland S.S., Krohg-Sørensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation, 2007; 115 (8): 972–80. doi: 10.1161/CIRCULATIONAHA.106.665893Xu F., Ning X., Zhao T., Lu Q., Chen H. Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose. Open Med. (Wars), 2022; 17 (1): 1405–1411. doi: 10.1515/med2022-0540Xu F., Ning X., Zhao T., Lu Q., Chen H. Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose. Open Med. (Wars), 2022; 17 (1): 1405–1411. doi: 10.1515/med2022-0540Wang X.H., Dou L.Z., Gu C., Wang X.Q. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac. J. Trop. Med., 2014; 7 (1): 55–62. doi: 10.1016/S19957645(13)60192-3Wang X.H., Dou L.Z., Gu C., Wang X.Q. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pac. J. Trop. Med., 2014; 7 (1): 55–62. doi: 10.1016/S19957645(13)60192-3Zheng M., Lu N., Ren M., Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC Cardiovasc. Disord., 2020; 20 (1): 271. doi: 10.1186/s12872-020-01549-3Zheng M., Lu N., Ren M., Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC Cardiovasc. Disord., 2020; 20 (1): 271. doi: 10.1186/s12872-020-01549-3Wu X.A., Xie G., Li X.Q., Wu H.T., Wang X. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents. Clin. Chim. Acta, 2018; 479: 20–24. doi: 10.1016/j.cca.2018.01.004Wu X.A., Xie G., Li X.Q., Wu H.T., Wang X. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents. Clin. Chim. Acta, 2018; 479: 20–24. doi: 10.1016/j.cca.2018.01.004Yu F., Li J., Huang Q., Cai H. Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies. Angiology, 2018; 69 (9): 825–834. doi: 10.1177/0003319718771125Yu F., Li J., Huang Q., Cai H. Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies. Angiology, 2018; 69 (9): 825–834. doi: 10.1177/0003319718771125Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol., 2021; 101: 107598. doi: 10.1016/j.intimp.2021.107598Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol., 2021; 101: 107598. doi: 10.1016/j.intimp.2021.107598Bremer A.A., Devaraj S., Afify A., Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab., 2011; 96 (11): E1782–E1788. doi: 10.1210/jc.2011-1577Bremer A.A., Devaraj S., Afify A., Jialal I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab., 2011; 96 (11): E1782–E1788. doi: 10.1210/jc.2011-1577Arner E., Mejhert N., Kulyté A., Balwierz P.J., Pachkov M., Cormont M., Lorente-Cebrián S., Ehrlund A., Laurencikiene J., Hedén P., Dahlman-Wright K., Tanti J.F., Hayashizaki Y., Rydén M., Dahlman I., van Nimwegen E., Daub C.O., Arner P. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes, 2012; 61 (8): 1986–1993. doi: 10.2337/db11-1508Arner E., Mejhert N., Kulyté A., Balwierz P.J., Pachkov M., Cormont M., Lorente-Cebrián S., Ehrlund A., Laurencikiene J., Hedén P., Dahlman-Wright K., Tanti J.F., Hayashizaki Y., Rydén M., Dahlman I., van Nimwegen E., Daub C.O., Arner P. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes, 2012; 61 (8): 1986–1993. doi: 10.2337/db11-1508Fuchs S., Lavi I., Tzang O., Bessler H., Brosh D., Bental T., Dvir D., Einav S., Kornowski R. Intracoronary monocyte chemoattractant protein 1 and vascular endothelial growth factor levels are associated with necrotic core, calcium and fibrous tissue atherosclerotic plaque components: an intracoronary ultrasound radiofrequency study. Cardiology, 2012; 123 (2): 125–132. doi: 10.1159/000342050Fuchs S., Lavi I., Tzang O., Bessler H., Brosh D., Bental T., Dvir D., Einav S., Kornowski R. Intracoronary monocyte chemoattractant protein 1 and vascular endothelial growth factor levels are associated with necrotic core, calcium and fibrous tissue atherosclerotic plaque components: an intracoronary ultrasound radiofrequency study. Cardiology, 2012; 123 (2): 125–132. doi: 10.1159/000342050Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., Ruotolo G., Luzi L., Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care, 2009; 32 (11): 2105–2110. doi: 10.2337/dc09-0763Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., Ruotolo G., Luzi L., Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care, 2009; 32 (11): 2105–2110. doi: 10.2337/dc09-0763Bianconi V., Sahebkar A., Atkin S.L., Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr. Opin. Hematol., 2018; 25 (1): 44– 51. doi: 10.1097/MOH.0000000000000389Bianconi V., Sahebkar A., Atkin S.L., Pirro M. The regulation and importance of monocyte chemoattractant protein-1. Curr. Opin. Hematol., 2018; 25 (1): 44– 51. doi: 10.1097/MOH.0000000000000389Schneiderman J., Sawdey M.S., Keeton M.R., Bordin G.M., Bernstein E.F., Dilley R.B., Loskutoff D.J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. U. S. A., 1992; 89 (15): 6998–7002. doi: 10.1073/pnas.89.15.6998Schneiderman J., Sawdey M.S., Keeton M.R., Bordin G.M., Bernstein E.F., Dilley R.B., Loskutoff D.J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. U. S. A., 1992; 89 (15): 6998–7002. doi: 10.1073/pnas.89.15.6998Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc. Ther., 2010; 28 (5): e72–e91. doi: 10.1111/j.1755-5922.2010.00171.xCesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc. Ther., 2010; 28 (5): e72–e91. doi: 10.1111/j.1755-5922.2010.00171.xOrenes-Piñero E., Pineda J., Roldán V., Hernández-Romero D., Marco P., Tello-Montoliu A., Sogorb F., Valdés M., Lip G.Y., Marín F. Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. J. Atheroscler. Thromb., 2015; 22 (6): 610–617. doi: 10.5551/jat.26161Orenes-Piñero E., Pineda J., Roldán V., HernándezRomero D., Marco P., Tello-Montoliu A., Sogorb F., Valdés M., Lip G.Y., Marín F. Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. J. Atheroscler. Thromb., 2015; 22 (6): 610–617. doi: 10.5551/jat.26161Chen R., Yan J., Liu P., Wang Z., Wang C. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab. Brain. Dis., 2017; 32 (3): 667–673. doi: 10.1007/s11011-017-0007-3Chen R., Yan J., Liu P., Wang Z., Wang C. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab. Brain. Dis., 2017; 32 (3): 667–673. doi: 10.1007/s11011-017-0007-3Tschoner A., Sturm W., Engl J., Kaser S., Laimer M., Laimer E., Klaus A., Patsch J.R., Ebenbichler C.F. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr. Metab. Cardiovasc. Dis., 2012; 22 (4): 340–346. doi: 10.1016/j.numecd.2010.07.009Tschoner A., Sturm W., Engl J., Kaser S., Laimer M., Laimer E., Klaus A., Patsch J.R., Ebenbichler C.F. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr. Metab. Cardiovasc. Dis., 2012; 22 (4): 340–346. doi: 10.1016/j.numecd.2010.07.009Barnard S.A., Pieters M., Nienaber-Rousseau C., Kruger H.S. Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women. Thromb. Res., 2016; 146: 95–102. doi: 10.1016/j.thromres.2016.09.003Barnard S.A., Pieters M., Nienaber-Rousseau C., Kruger H.S. Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women. Thromb. Res., 2016; 146: 95–102. doi: 10.1016/j.thromres.2016.09.003Barbato A., Iacone R., Tarantino G., Russo O., Sorrentino P., Avallone S., Galletti F., Farinaro E., Della Valle E., Strazzullo P. Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern. Emerg. Med., 2009; 4 (4): 315–323. doi: 10.1007/s11739-009-0240-9Barbato A., Iacone R., Tarantino G., Russo O., Sorrentino P., Avallone S., Galletti F., Farinaro E., Della Valle E., Strazzullo P. Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern. Emerg. Med., 2009; 4 (4): 315–323. doi: 10.1007/s11739-009-0240-9Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L., Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism, 1990; 39 (10): 1044–1048. doi: 10.1016/0026-0495(90)90164-8Landin K., Stigendal L., Eriksson E., Krotkiewski M., Risberg B., Tengborn L., Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabo-lism, 1990; 39 (10): 1044–1048. doi: 10.1016/0026-0495(90)90164-8Bilgic Gazioglu S., Akan G., Atalar F., Erten G. PAI1 and TNF-α profiles of adipose tissue in obese cardiovascular disease patients. Int. J. Clin. Exp. Pathol., 2015; 8 (12): 15919–15925. ISSN: 1936-2625Bilgic Gazioglu S., Akan G., Atalar F., Erten G. PAI1 and TNF- profiles of adipose tissue in obese cardiovascular disease patients. Int. J. Clin. Exp. Pathol., 2015; 8 (12): 15919–15925. ISSN: 1936-2625Shimizu T., Uematsu M., Yoshizaki T., Obata J.E., Nakamura T., Fujioka D., Watanabe K., Watanabe Y., Kugiyama K. Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction. J. Atheroscler. Thromb., 2016; 23 (5): 557–566. doi: 10.5551/jat.32300Shimizu T., Uematsu M., Yoshizaki T., Obata J.E., Nakamura T., Fujioka D., Watanabe K., Watanabe Y., Kugiyama K. Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction. J. Atheroscler. Thromb., 2016; 23 (5): 557–566. doi: 10.5551/jat.32300Liang Z., Jiang W., Ouyang M., Yang K. PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis. Int. J. Clin. Exp. Med., 2015; 8 (2): 2097–2107. ISSN: 1940-5901Liang Z., Jiang W., Ouyang M., Yang K. PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis. Int. J. Clin. Exp. Med., 2015; 8 (2): 2097–2107. ISSN: 1940-5901Choi K.M., Lee J.S., Kim E.J., Baik S.H., Seo H.S., Choi D.S., Oh D.J., Park C.G. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol., 2008; 158 (2): 203–207. doi: 10.1530/EJE-07-0633Choi K.M., Lee J.S., Kim E.J., Baik S.H., Seo H.S., Choi D.S., Oh D.J., Park C.G. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol., 2008; 158 (2): 203–207. doi: 10.1530/EJE-07-0633Ni J., Ma X., Zhou M., Pan X., Tang J., Hao Y., Lu Z., Gao M., Bao Y., Jia W. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc. Diabetol., 2013; 12: 176. doi: 10.1186/1475-2840-12-176Ni J., Ma X., Zhou M., Pan X., Tang J., Hao Y., Lu Z., Gao M., Bao Y., Jia W. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc. Diabetol., 2013; 12: 176. doi: 10.1186/1475-2840-12-176Li C., Zhang Z., Peng Y., Gao H., Wang Y., Zhao J., Pan C. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One, 2019; 14 (8): e0220841. doi: 10.1371/journal.pone.0220841Li C., Zhang Z., Peng Y., Gao H., Wang Y., Zhao J., Pan C. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. PLoS One, 2019; 14 (8): e0220841. doi: 10.1371/journal.pone.0220841Shibata K., Sato K., Shirai R., Seki T., Okano T., Yamashita T., Koide A., Mitsuboshi M., Mori Y., Hirano T., Watanabe T. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. Heart Vessels, 2020; 35 (7): 1012–1024. doi: 10.1007/s00380-020-01556-6Shibata K., Sato K., Shirai R., Seki T., Okano T., Yamashita T., Koide A., Mitsuboshi M., Mori Y., Hirano T., Watanabe T. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. Heart Vessels, 2020; 35 (7): 1012–1024. doi: 10.1007/s00380-020-01556-6Oberoi R., Bogalle E.P., Matthes L.A., Schuett H., Koch A.K., Grote K., Schieffer B., Schuett J., Luchtefeld M. Lipocalin (LCN) 2 Mediates Pro-Atherosclerotic Processes and Is Elevated in Patients with Coronary Artery Disease. PLoS One, 2015; 10 (9): e0137924. doi: 10.1371/journal.pone.0137924Oberoi R., Bogalle E.P., Matthes L.A., Schuett H., Koch A.K., Grote K., Schieffer B., Schuett J., Luchtefeld M. Lipocalin (LCN) 2 Mediates Pro-Atherosclerotic Processes and Is Elevated in Patients with Coronary Artery Disease. PLoS One, 2015; 10 (9): e0137924. doi: 10.1371/journal.pone.0137924Soylu K., Aksan G., Nar G., Özdemir M., Gülel O., İnci S., Aksakal A., Soylu Aİ., Yılmaz Ö. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol. J. Cardiol., 2015; 15 (6): 450–455. doi: 10.5152/akd.2014.5513Soylu K., Aksan G., Nar G., Özdemir M., Gülel O., İnci S., Aksakal A., Soylu Aİ., Yılmaz Ö. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Anatol. J. Cardiol., 2015; 15 (6): 450–455. doi: 10.5152/akd.2014.5513Lahiri A., Alex A.G., George P.V. Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes. Indian. Heart J., 2018; 70 (2): 220–224. doi: 10.1016/j.ihj.2017.06.005Lahiri A., Alex A.G., George P.V. Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes. Indian. Heart J., 2018; 70 (2): 220–224. doi: 10.1016/j.ihj.2017.06.005Chen Y., Fu Y., Wang S., Chen P., Pei Y., Zhang J., Zhang R., Niu G., Gu F., Li X. Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥ 65 years. Cardiovasc. Diabetol., 2022; 21 (1): 252. doi: 10.1186/s12933-02201668-5Chen Y., Fu Y., Wang S., Chen P., Pei Y., Zhang J., Zhang R., Niu G., Gu F., Li X. Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged  65 years. Cardiovasc. Diabetol., 2022; 21 (1): 252. doi: 10.1186/s12933-02201668-5Peng W., Zhang C., Wang Z., Yang W., Luo H., Li X., Fu D., Yu C., Zhou Y. Prognostic value of neutrophil gelatinase-associated lipocalin and glycosylated hemoglobin for non-ST-segment elevation myocardial infarction patients with single concomitant chronic total occlusion following primary percutaneous coronary intervention: A prospective observational study. Medicine (Baltimore), 2019; 98 (39): e16982. doi: 10.1097/MD.0000000000016982Peng W., Zhang C., Wang Z., Yang W., Luo H., Li X., Fu D., Yu C., Zhou Y. Prognostic value of neutrophil gelatinase-associated lipocalin and glycosylated hemoglobin for non-ST-segment elevation myocardial infarction patients with single concomitant chronic total occlusion following primary percutaneous coronary intervention: A prospective observational study. Medicine (Baltimore), 2019; 98 (39): e16982. doi: 10.1097/MD.0000000000016982Kim M., Oh J.K., Sakata S., Liang I., Park W., Hajjar R.J., Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J. Mol. Cell Cardiol., 2008; 45 (2): 270–280. doi: 10.1016/j.yjmcc.2008.05.006Kim M., Oh J.K., Sakata S., Liang I., Park W., Hajjar R.J., Lebeche D. Role of resistin in cardiac contractility and hypertrophy. J. Mol. Cell Cardiol., 2008; 45 (2): 270–280. doi: 10.1016/j.yjmcc.2008.05.006Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mech. Ageing. Dev., 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mech. Ageing. Dev., 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004Тепляков А.Т., Ахмедов Ш.Д., Суслова Т.Е., Андриянова А.В., Кузнецова А.В., Протопопова Н.В., Калюжин В.В., Насанова О.Н. Влияние резистина на течение ишемической болезни сердца у пациентов с сахарным диабетом 2-го типа. Бюл. сиб. мед., 2015; 14 (5): 73–82. doi: 10.20538/16820363-2015-5-73-82Teplyakov A.T., Akhmedov S.D., Suslova T.Y., Andriyanova А.V., Kuznetsova A.V., Protopopova N.V., Kalyuzhin V.V., Nasanova O.N. Influence of resistin on the course of ischemic heart disease in patients with type 2 diabetes mellitus. Bulletin of Siberian Medicine, 2015; 14 (5): 73–82. doi: 10.20538/1682-0363-2015-5-73-82 (In Russ.).Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak. J. Med. Sci., 2019; 35(3): 641–646. doi:10.12669/pjms.35.3.274Niaz S., Latif J., Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak. J. Med. Sci., 2019; 35(3): 641–646. doi:10.12669/pjms.35.3.274Заковряшина И.Н., Хаишева Л.А., Шлык С.В. Изучение уровня резистина и липидного профиля у пациентов с инфарктом миокарда с подъемом сегмента ST, результаты годового наблюдения. Атеросклероз и дислипидемии, 2022; 4 (45): 51–58. doi: 10.34687/2219-8202.JAD.2021.04.0006Zakovryashina I.N., Khaisheva L.A., Shlyk S.V. Study of the level of resistin and lipid profile in patients with myocardial infarction with ST segment elevation, results of annual follow-up. The Journal of Atherosclerosis and Dyslipidemias, 2022; 4 (45): 51–58. doi: 10.34687/2219-8202.JAD.2021.04.0006 82 (In Russ.).Авсарагова А.З., Астахова З.Т., Ремизов О.В. Влияние адипокина резистина на риск развития сердечно-сосудистых осложнений у больных острым коронарным синдромом. Вестн. новых мед. технологий, 2019; 4: 49–52. doi: 10.24411/1609-2163-201916513Avsaragov A.Z., Astakhova Z.T., Remizov O.V. The effect of adiponectin resistin on the risk of cardiovascular complications in patients with acute coronary syndrome. Bulletin of New Medical Technologies, 2019; 4: 49–52. doi: 10.24411/1609-2163-2019-16513 (In Russ.).Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin is increased in patients with unstable angina. Chin. Med. J. (Engl). 2007; 120 (10): 871–875.Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin is increased in patients with unstable angina. Chin. Med. J. (Engl). 2007; 120 (10): 871–875.On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ. J., 2007; 71 (6): 868–873. doi: 10.1253/circj.71.868On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ. J., 2007; 71 (6): 868–873. doi: 10.1253/circj.71.868Zhang J.Z., Gao Y., Zheng Y.Y., Liu F., Yang Y.N., Li X.M., Ma X., Ma Y.T., Xie X. Increased serum resistin level is associated with coronary heart disease. Oncotarget, 2017; 8 (30): 50148–50154. doi: 10.18632/oncotargetZhang J.Z., Gao Y., Zheng Y.Y., Liu F., Yang Y.N., Li X.M., Ma X., Ma Y.T., Xie X. Increased serum resistin level is associated with coronary heart disease. Oncotarget, 2017; 8 (30): 50148–50154. doi: 10.18632/oncotargetChen D., Zhang Y., Yidilisi A., Xu Y., Dong Q., Jiang J. Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study. J. Clin. Endocrinol. Metab., 2022; 107 (6): e2572–e2580. doi: 10.1210/clinem/dgac048Chen D., Zhang Y., Yidilisi A., Xu Y., Dong Q., Jiang J. Causal Associations Between Circulating Adipokines and Cardiovascular Disease: A Mendelian Randomization Study. J. Clin. Endocrinol. Metab., 2022; 107 (6): e2572–e2580. doi: 10.1210/clinem/dgac048Mauer J., Denson J.L., Bruning J.C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol., 2015: 36 (2): 92–101 doi: 10.1016/j.it.2014.12.008Mauer J., Denson J.L., Bruning J.C. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol., 2015: 36 (2): 92–101 doi: 10.1016/j.it.2014.12.008Mauer J., Chaurasia B., Goldau J., Vogt M.C., Ruud J., Nguyen K.D. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol., 2014; 15 (5): 423–430. doi: 10.1038/ni.2865Mauer J., Chaurasia B., Goldau J., Vogt M.C., Ruud J., Nguyen K.D. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol., 2014; 15 (5): 423–430. doi: 10.1038/ni.2865Yaseen F., Jaleel A., Aftab J., Zuberi A., Alam E. Circulating levels of resistin, IL-6 and lipid profile in elderly patients with ischemic heart disease with and without diabetes. Biomark Med., 2012; 6 (1): 97–102. doi: 10.2217/bmm.11.104Yaseen F., Jaleel A., Aftab J., Zuberi A., Alam E. Circulating levels of resistin, IL-6 and lipid profile in elderly patients with ischemic heart disease with and without diabetes. Biomark Med., 2012; 6 (1): 97–102. doi: 10.2217/bmm.11.104Cheng K.H., Chu C.S., Lee K.T., Lin T.H., Hsieh C.C., Chiu C.C., Voon W.C., Sheu S.H., Lai W.T. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int. J. Obes. (Lond), 2008; 32 (2): 268–274. doi: 10.1038/sj.ijo.0803726Cheng K.H., Chu C.S., Lee K.T., Lin T.H., Hsieh C.C., Chiu C.C., Voon W.C., Sheu S.H., Lai W.T. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int. J. Obes. (Lond), 2008; 32 (2): 268–274. doi: 10.1038/sj.ijo.0803726Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA, 2002; 288 (8): 980–987. doi: 10.1001/jama.288.8.980Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA, 2002; 288 (8): 980–987. doi: 10.1001/jama.288.8.980Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., Mabuchi N., Sawaki M., Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol., 1998; 31 (2): 391–398. doi: 10.1016/s0735-1097(97)00494-4Tsutamoto T., Hisanaga T., Wada A., Maeda K., Ohnishi M., Fukai D., Mabuchi N., Sawaki M., Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol., 1998; 31 (2): 391–398. doi: 10.1016/s0735-1097(97)00494-4Tajfard M., Latiff L.A., Rahimi H.R., Moohebati M., Hasanzadeh M., Emrani A.S., Esmaeily H., Taghipour A., Mirhafez S.R., Ferns G.A., Mardan-Nik M., Mohammadzadeh E., Avan A., Hanachi P., Ghayour-Mobarhan M. Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography. Mol. Cell Biochem., 2017; 435 (1-2): 37–45. doi: 10.1007/s11010-0173054-5Tajfard M., Latiff L.A., Rahimi H.R., Moohebati M., Hasanzadeh M., Emrani A.S., Esmaeily H., Taghipour A., Mirhafez S.R., Ferns G.A., MardanNik M., Mohammadzadeh E., Avan A., Hanachi P., Ghayour-Mobarhan M. Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography. Mol. Cell Biochem., 2017; 435 (1-2): 37–45. doi: 10.1007/s11010-0173054-5Antonopoulos A.S., Angelopoulos A., Papanikolaou P., Simantiris S., Oikonomou E.K., Vamvakaris K., Koumpoura A., Farmaki M., Trivella M., Vlachopoulos C., Tsioufis K., Antoniades C., Tousoulis D. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC Cardiovasc. Imaging., 2022; 15 (3): 460–471. doi: 10.1016/j.jcmg.2021.09.014Antonopoulos A.S., Angelopoulos A., Papanikolaou P., Simantiris S., Oikonomou E.K., Vamvakaris K., Koumpoura A., Farmaki M., Trivella M., Vlachopoulos C., Tsioufis K., Antoniades C., Tousoulis D. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC Cardiovasc. Imaging., 2022; 15 (3): 460–471. doi: 10.1016/j.jcmg.2021.09.014Kaptoge S., Seshasai S.R., Gao P., Freitag D.F., Butterworth A.S., Borglykke A., di Angelantonio E., Gudnason V., Rumley A., Lowe G.D., Jørgensen T., Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur. Heart J., 2014; 35 (9): 578–589. doi: 10.1093/eurheartj/eht367Kaptoge S., Seshasai S.R., Gao P., Freitag D.F., Butterworth A.S., Borglykke A., di Angelantonio E., Gudnason V., Rumley A., Lowe G.D., Jørgensen T., Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur. Heart J., 2014; 35 (9): 578–589. doi: 10.1093/eurheartj/eht367Blum W.F., Englaro P., Hanitsch S., Juul A., Hertel N.T., Müller J., Skakkebaek N.E., Heiman M.L., Birkett M., Attanasio A.M., Kiess W., Rascher W. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J. Clin. Endocrinol. Metab., 1997; 82 (9): 2904–2910. doi: 10.1210/jcem.82.9.4251Blum W.F., Englaro P., Hanitsch S., Juul A., Hertel N.T., Müller J., Skakkebaek N.E., Heiman M.L., Birkett M., Attanasio A.M., Kiess W., Rascher W. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J. Clin. Endocrinol. Metab., 1997; 82 (9): 2904–2910. doi: 10.1210/jcem.82.9.4251Bigalke B., Stellos K., Geisler T., Seizer P., Mozes V., Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets, 2010; 21 (1): 11–19. doi: 10.3109/09537100903377584Bigalke B., Stellos K., Geisler T., Seizer P., Mozes V., Gawaz M. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease. Platelets, 2010; 21 (1): 11–19. doi: 10.3109/09537100903377584Anagnostoulis S., Karayiannakis A.J., Lambropoulou M., Efthimiadou A., Polychronidis A, Simopoulos C. Human leptin induces angiogenesis in vivo. Cytokine, 2008; 42 (3): 353–357. doi: 10.1016/j.cyto.2008.03.009Anagnostoulis S., Karayiannakis A.J., Lambropoulou M., Efthimiadou A., Polychronidis A, Simopoulos C. Human leptin induces angiogenesis in vivo. Cytokine, 2008; 42 (3): 353–357. doi: 10.1016/j.cyto.2008.03.009Chai S.B., Sun F., Nie X.L., Wang J. Leptin and coronary heart disease: a systematic review and meta-analysis. Atherosclerosis, 2014; 233 (1): 3–10. doi: 10.1016/j.atherosclerosis.2013.11.069Chai S.B., Sun F., Nie X.L., Wang J. Leptin and coronary heart disease: a systematic review and meta-analysis. Atherosclerosis, 2014; 233 (1): 3–10. doi: 10.1016/j.atherosclerosis.2013.11.069Yang H., Guo W., Li J., Cao S., Zhang J., Pan J., Wang Z., Wen P., Shi X., Zhang S. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. PLoS One, 2017; 12 (3): e0166360. doi: 10.1371/journal.pone.0166360Yang H., Guo W., Li J., Cao S., Zhang J., Pan J., Wang Z., Wen P., Shi X., Zhang S. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. PLoS One, 2017; 12 (3): e0166360. doi: 10.1371/journal.pone.0166360Zeng R., Xu C.H., Xu Y.N., Wang Y.L., Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq. Bras. Endocrinol. Metabol., 2014; 58 (8): 817– 823. doi: 10.1590/0004-2730000003390Zeng R., Xu C.H., Xu Y.N., Wang Y.L., Wang M. Association of leptin levels with pathogenetic risk of coronary heart disease and stroke: a meta-analysis. Arq. Bras. Endocrinol. Metabol., 2014; 58 (8): 817– 823. doi: 10.1590/0004-2730000003390Rahmani A., Toloueitabar Y., Mohsenzadeh Y. Hemmati R., Sayehmiri K., Asadollahi K. Association between plasma leptin/adiponectin ratios with the extent and severity of coronary artery disease. BMC Cardiovasc. Disord., 2020; 20 (1): 474. doi: 10.1186/s12872020-01723-7Rahmani A., Toloueitabar Y., Mohsenzadeh Y. Hemmati R., Sayehmiri K., Asadollahi K. Association between plasma leptin/adiponectin ratios with the extent and severity of coronary artery disease. BMC Cardiovasc. Disord., 2020; 20 (1): 474. doi: 10.1186/s12872020-01723-7Полякова Е.А. Роль растворимых рецепторов лептина в патогенезе ишемической болезни сердца. Регионарное кровообращение и микроциркуляция, 2021; 20 (3): 34–45. doi: 10.24884/1682-6655-202120-3-34-45Polyakova E.A. The role of soluble leptin receptor in the pathogenesis of coronary heart disease. Regional blood circulation and microcirculation, 2021; 20 (3): 34–45. doi: 10.24884/1682-6655-2021-20-334-45 (In Russ.).Драпкина О.М., Корнеева О.Н., Палаткина Л.О. Адипокины и сердечно-сосудистые заболевания: патогенетические параллели и терапевтические перспективы. Артериальная гипертензия, 2011; 17 (3): 203–208. doi: 10.18705/1607-419X-2011-173-203-208Drapkina O.M., Korneeva O.N., Palatkina L.O. Adipokines and cardiovascular diseases: pathogenesis and therapeutic strategies. Arterial’naya gipertenziya (Arterial Hypertension), 2011; 17 (3): 203–208. doi: 10.18705/1607-419X-2011-17-3-203-208 (In Russ.).Bergh N., Ulfhammer E., Glise K., Jern S., Karlsson L. Influence of TNF-alpha and biomechanical stress on endothelial antiand prothrombotic genes. Biochem. Biophys. Res. Commun., 2009; 385 (3): 314– 318. doi: 10.1016/j.bbrc.2009.05.046Bergh N., Ulfhammer E., Glise K., Jern S., Karlsson L. Influence of TNF-alpha and biomechanical stress on endothelial antiand prothrombotic genes. Biochem. Biophys. Res. Commun., 2009; 385 (3): 314– 318. doi: 10.1016/j.bbrc.2009.05.046Hu J., Liu X., Tang Y. HMGB1/Foxp1 regulates hypoxia-induced inflammatory response in macrophages. Cell Biol. Int., 2022; 46 (2): 265–277. doi: 10.1002/cbin.11728Hu J., Liu X., Tang Y. HMGB1/Foxp1 regulates hypoxia-induced inflammatory response in macrophages. Cell Biol. Int., 2022; 46 (2): 265–277. doi: 10.1002/cbin.11728Gonzálvez M., Ruiz-Ros J.A., Pérez-Paredes M., Lozano M.L., García-Almagro F.J., Martínez-Corbalán F., Giménez D.M., Carrillo A., Carnero A., Cubero T., Gonzálvez J.J., Ureña I., Vicente V. Valor pronóstico del factor de necrosis tumoral alfa en pacientes con infarto agudo de miocardio con elevación del segmento ST [Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev. Esp. Cardiol., 2007; 60 (12): 1233–1241. doi: 10.1157/13113928 (In Spanish)Gonzálvez M., Ruiz-Ros J.A., Pérez-Paredes M., Lozano M.L., García-Almagro F.J., Martínez-Corbalán F., Giménez D.M., Carrillo A., Carnero A., Cubero T., Gonzálvez J.J., Ureña I., Vicente V. Valor pronóstico del factor de necrosis tumoral alfa en pacientes con infarto agudo de miocardio con elevación del segmento ST [Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction]. Rev. Esp. Cardiol., 2007; 60 (12): 1233–1241. doi: 10.1157/13113928 (In Spanish)Paccalet A., Crola Da Silva C., Mechtouff L., Amaz C., Varillon Y., de Bourguignon C., Cartier R., Prieur C., Tomasevic D., Genot N., Leboube S., Derimay F., Rioufol G., Bonnefoy-Cudraz E., Mewton N., Ovize M., Bidaux G., Bochaton T. Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction. Front. Pharmacol., 2021; 12: 656928. doi: 10.3389/fphar.2021.656928Paccalet A., Crola Da Silva C., Mechtouff L., Amaz C., Varillon Y., de Bourguignon C., Cartier R., Prieur C., Tomasevic D., Genot N., Leboube S., Derimay F., Rioufol G., Bonnefoy-Cudraz E., Mewton N., Ovize M., Bidaux G., Bochaton T. Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction. Front. Pharmacol., 2021; 12: 656928. doi: 10.3389/fphar.2021.656928Yuan S., Carter P., Bruzelius M., Vithayathil M., Kar S., Mason A.M., Lin A., Burgess S., Larsson S.C. Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine, 2020; 59: 102956. doi: 10.1016/j.ebiom.2020.102956Yuan S., Carter P., Bruzelius M., Vithayathil M., Kar S., Mason A.M., Lin A., Burgess S., Larsson S.C. Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine, 2020; 59: 102956. doi: 10.1016/j.ebiom.2020.102956

The authors declare that there are no conflicts of interest present.